Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a report issued on Monday. The firm set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research raised Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th.

Accelerate Diagnostics Trading Up 4.7 %

Shares of AXDX stock opened at $1.12 on Monday. The business’s 50 day moving average is $1.37 and its two-hundred day moving average is $1.54. Accelerate Diagnostics has a 12-month low of $0.73 and a 12-month high of $2.09. The company has a market capitalization of $28.04 million, a P/E ratio of -0.39 and a beta of 0.59.

Insider Buying and Selling

In other Accelerate Diagnostics news, Director John Patience bought 200,000 shares of Accelerate Diagnostics stock in a transaction on Tuesday, December 3rd. The shares were bought at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the completion of the transaction, the director now directly owns 653,224 shares of the company’s stock, valued at $1,025,561.68. This trade represents a 44.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 43.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Accelerate Diagnostics

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd acquired a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Accelerate Diagnostics at the end of the most recent quarter. 17.14% of the stock is owned by hedge funds and other institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.